IL195580A - L – fkbp polypeptides, preparations containing them, methods of preparation and use - Google Patents

L – fkbp polypeptides, preparations containing them, methods of preparation and use

Info

Publication number
IL195580A
IL195580A IL195580A IL19558008A IL195580A IL 195580 A IL195580 A IL 195580A IL 195580 A IL195580 A IL 195580A IL 19558008 A IL19558008 A IL 19558008A IL 195580 A IL195580 A IL 195580A
Authority
IL
Israel
Prior art keywords
same
fkbp
polypeptides
compositions
preparing
Prior art date
Application number
IL195580A
Other languages
English (en)
Hebrew (he)
Other versions
IL195580A0 (en
Original Assignee
Almac Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Sciences Ltd filed Critical Almac Sciences Ltd
Publication of IL195580A0 publication Critical patent/IL195580A0/en
Publication of IL195580A publication Critical patent/IL195580A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
IL195580A 2006-06-09 2008-11-27 L – fkbp polypeptides, preparations containing them, methods of preparation and use IL195580A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0611405.2A GB0611405D0 (en) 2006-06-09 2006-06-09 FKBP-L: A novel inhibitor of angiogenesis
PCT/GB2007/002107 WO2007141533A2 (en) 2006-06-09 2007-06-08 Fkbp-l and uses thereof

Publications (2)

Publication Number Publication Date
IL195580A0 IL195580A0 (en) 2011-08-01
IL195580A true IL195580A (en) 2013-07-31

Family

ID=36745574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195580A IL195580A (en) 2006-06-09 2008-11-27 L – fkbp polypeptides, preparations containing them, methods of preparation and use

Country Status (18)

Country Link
US (3) US9381228B2 (enExample)
EP (1) EP2040728B1 (enExample)
JP (1) JP5474535B2 (enExample)
CN (1) CN101489575B (enExample)
AU (1) AU2007255196B2 (enExample)
CA (1) CA2657947C (enExample)
CY (1) CY1116970T1 (enExample)
DK (1) DK2040728T3 (enExample)
ES (1) ES2548332T3 (enExample)
GB (1) GB0611405D0 (enExample)
HU (1) HUE028099T2 (enExample)
IL (1) IL195580A (enExample)
NZ (2) NZ573425A (enExample)
PL (1) PL2040728T3 (enExample)
PT (1) PT2040728E (enExample)
SI (1) SI2040728T1 (enExample)
WO (1) WO2007141533A2 (enExample)
ZA (1) ZA200810323B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
GB0724393D0 (en) * 2007-12-14 2008-01-23 Univ Ulster Use of FKBPL gene to identify a cause of infertility
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB0908589D0 (en) 2009-05-19 2009-06-24 Univ Belfast Assay method
WO2011008260A2 (en) * 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
US20140308260A1 (en) * 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA3113959A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP3782638A1 (en) 2013-03-13 2021-02-24 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
WO2014201370A1 (en) 2013-06-14 2014-12-18 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
CN114805527A (zh) 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
DK3402480T3 (da) 2016-01-11 2021-06-28 Epicentrx Inc Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon
WO2017136312A1 (en) 2016-02-02 2017-08-10 Splash Pharmaceuticals, Inc. Combination therapy with a6, chemotherapeutic agents, radiation therapy, or a combination thereof for the treatment of cancer
US20190231847A1 (en) * 2016-06-22 2019-08-01 Almac Discovery Limited Treatment of ocular disease
WO2018071741A1 (en) 2016-10-14 2018-04-19 Epicentrix, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
EP3528831B1 (en) 2016-10-19 2022-09-21 Royal College of Surgeons in Ireland Use of fkbp-l polypeptides and nucleic acids for the treatment of obesity
CN108362870A (zh) * 2017-01-27 2018-08-03 武汉三鹰生物技术有限公司 一种用于人fkbpl蛋白的酶联免疫检测及制备方法
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
CN113702632A (zh) * 2021-09-02 2021-11-26 深圳市光与生物科技有限公司 一种快速检测子痫前期的免疫层析检测卡及其制备方法与应用
CN114702564A (zh) * 2021-12-15 2022-07-05 江苏省人民医院（南京医科大学第一附属医院） 一种外泌体肽及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194732A (en) 1960-10-03 1965-07-13 Neuhauser Irene Assisting healing of skin-denuded areas on the body with dried non-fibrous egg-shellmembrane products and compositions therefor
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JP3065628B2 (ja) * 1988-12-19 2000-07-17 三井化学株式会社 ヒト免疫グロブリン遺伝子関連ｄｎａ断片及び該ｄｎａ断片を用いる診断方法
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
AU648140B2 (en) 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
NZ266622A (en) * 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
AU7248896A (en) * 1995-10-11 1997-04-30 Chiron Corporation Combination pdgf, kgf, igf and igfbp for wound healing
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
US6583168B1 (en) 1997-11-25 2003-06-24 Applera Corporation Sulfonated diarylrhodamine dyes
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2331382A1 (en) * 1998-06-18 1999-12-23 Curagen Corporation Interaction of p27(kip1) with fkbp-12
WO2000021992A1 (en) * 1998-10-09 2000-04-20 Shanghai Second Medical University A human fk506 binding protein (fkbp)
US6413607B1 (en) 1999-04-13 2002-07-02 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Cyanine dyes
AU771904B2 (en) * 1999-06-22 2004-04-08 Research Development Foundation Enhanced wound coverage to enhance wound healing
AU6074000A (en) * 1999-07-06 2001-01-22 Incyte Genomics, Inc. Human immune response molecules
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20030125246A9 (en) * 2000-01-31 2003-07-03 Rosen Craig A. Nucleic acids, proteins, and antibodies
JP2004526425A (ja) * 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
ATE522603T1 (de) * 2001-06-22 2011-09-15 Hoffmann La Roche Löslicher komplex, der retrovirale oberflächen- glykoproteine und fkpa oder slyd enthält
US6856185B2 (en) * 2001-10-23 2005-02-15 Arris International, Inc. Simple RMS to DC converter
US20040053388A1 (en) * 2002-01-03 2004-03-18 Eckert Jorg H. Detection of protein conformation using a split ubiquitin reporter system
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
US10577406B2 (en) 2020-03-03
CA2657947A1 (en) 2007-12-13
WO2007141533A3 (en) 2008-07-31
IL195580A0 (en) 2011-08-01
AU2007255196A1 (en) 2007-12-13
HUE028099T2 (en) 2016-11-28
JP5474535B2 (ja) 2014-04-16
JP2009539367A (ja) 2009-11-19
PT2040728E (pt) 2015-10-29
US20090192085A1 (en) 2009-07-30
EP2040728B1 (en) 2015-09-02
CN101489575B (zh) 2013-08-28
SI2040728T1 (sl) 2015-12-31
CN101489575A (zh) 2009-07-22
AU2007255196B2 (en) 2013-10-03
NZ573425A (en) 2012-07-27
PL2040728T3 (pl) 2016-02-29
DK2040728T3 (en) 2015-10-26
CA2657947C (en) 2017-11-21
US9381228B2 (en) 2016-07-05
NZ600690A (en) 2014-03-28
ZA200810323B (en) 2013-05-29
EP2040728A2 (en) 2009-04-01
ES2548332T3 (es) 2015-10-15
CY1116970T1 (el) 2017-04-05
US20160340401A1 (en) 2016-11-24
US20160340402A1 (en) 2016-11-24
GB0611405D0 (en) 2006-07-19
WO2007141533A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
ZA200710108B (en) Layered composition and processes for preparing and using the composition
EP2076604A4 (en) GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
IL197185A (en) Anilid noble is preserved, the composition of its pharmacy and its uses
IL200746A0 (en) Cyclopamine analog compounds, compositions comprising the same and uses thereof
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
IL212836A0 (en) Azaquinolinone derivatives, compositions comprising the same and uses thereof
ZA200704865B (en) Layered composition and processes for preparing and using the composition
IL204621A0 (en) Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
IL205036A (en) Polypeptides, pharmaceutical preparations containing their uses and a nucleic acid encoding them
IL199680A0 (en) Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof
IL210722A0 (en) Benzazepine derivatives, compositions comprising the same and uses thereof
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
IL204211A (en) 2epha antidote, a drug containing it and its uses
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
IL190781A0 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
GB0601143D0 (en) Uses, methods and compositions
ZA200801988B (en) 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
IL196292A0 (en) Csf3r polypeptides, their preparation and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
KB Patent renewed
KB Patent renewed